RxDoctor Payments Data

Patrick Egbe, MD

Cardiovascular Disease · McDonough, GANPI 1699762419

Payments from drug & device makers

$1,463in general payments, 2019–2025

Across 60 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$262
  • Pfizer$182
  • Bridgebio Pharma, Inc.$152
  • E.r. Squibb & Sons, L.L.C.$138
  • Boehringer Ingelheim$125
  • Astellas Pharma US Inc$100
  • plus $505 from 15 others

What the payments were for

  • Food & beverage$1,16980%
  • Education$29520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,463 in reported general payments places this provider in the 35th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$120,221
Medicare patients
272
Services billed
1,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban285$266,080
EntrestoSacubitril/Valsartan145$134,926
JardianceEmpagliflozin72$70,009
FarxigaDapagliflozin Propanediol94$68,622
XareltoRivaroxaban32$41,712
Repatha SureclickEvolocumab27$29,152
Isosorbide Dinit-HydralazineIsosorbide Dinit/Hydralazine18$3,498
Atorvastatin Calcium509$3,378
Ranolazine ErRanolazine30$3,119
Clonidine24$2,966
Metoprolol Succinate197$1,748
Carvedilol280$1,610
Potassium Chloride120$1,590
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide42$1,461
Amlodipine-ValsartanAmlodipine Besylate/Valsartan44$1,366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$182$266,080285 claims
NovartisEntresto$70$134,926145 claims
Boehringer IngelheimJardiance$125$70,00972 claims
AstraZenecaFarxiga$18$68,62294 claims
Johnson & JohnsonXarelto$81$41,71232 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →